Dataset Information


Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease.

ABSTRACT: Three long-acting muscarinic antagonists (LAMAs) are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease. The first LAMA, tiotropium, has been widely used over the last decade as a once-daily maintenance therapy in stable COPD to improve patients' health-related quality of life and to reduce the risk of exacerbations. Administered via the HandiHaler(®) device, it is safe and well tolerated. Another new once-daily LAMA, glycopyrronium, has also been shown to improve health status and reduce exacerbations, and is well tolerated. The subject of this review is a third LAMA, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment. In the pivotal Phase III clinical trials, patients receiving aclidinium achieved significantly greater improvements in lung function, reductions in breathlessness, and improvements in health status compared with placebo, for up to 24 weeks. In continuation studies, these improvements were sustained for up to 52 weeks. Pooled data showed exacerbation frequency was significantly reduced with aclidinium versus placebo. Preclinical and pharmacological studies demonstrating low systemic bioavailability and a low propensity to induce cardiac arrhythmias were translated into a favorable tolerability profile in the clinical trial program - the adverse event profile of aclidinium was similar to placebo, with a low incidence of anticholinergic and cardiac adverse events. While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment.


PROVIDER: S-EPMC4381904 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4531806 | BioStudies
2013-01-01 | S-EPMC3787813 | BioStudies
2016-01-01 | S-EPMC5174811 | BioStudies
2019-01-01 | S-EPMC6535700 | BioStudies
1000-01-01 | S-EPMC5870740 | BioStudies
2014-01-01 | S-EPMC4213545 | BioStudies
2016-01-01 | S-EPMC5152596 | BioStudies
2019-01-01 | S-EPMC6396834 | BioStudies
2019-01-01 | S-EPMC6506885 | BioStudies
2017-01-01 | S-EPMC5476673 | BioStudies